1121586-29-5

Usage

Uses

Used in Scientific Research:
Methyl 3-iodo-4-fluorobenzoate is used as a research chemical for its ability to engage in various chemical reactions, particularly in the synthesis of complex organic structures.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Methyl 3-iodo-4-fluorobenzoate is utilized as a key intermediate in the synthesis of halogenated benzene derivatives, which are important in the development of new drugs and pharmaceutical compounds.
Key properties of Methyl 3-iodo-4-fluorobenzoate, such as its molecular weight, boiling and melting points, density, and refractive index, are essential for understanding its behavior in chemical reactions and its potential applications in research and development.
It is important to handle Methyl 3-iodo-4-fluorobenzoate with care and follow safety guidelines due to its potential reactivity, as is the case with most chemicals.

InChI:InChI=1S/C8H6FIO2/c1-12-8(11)5-2-3-6(9)7(10)4-5/h2-4H,1H3

Upstream product

• 110-58-7 n-Pentylamine 
• 2365-85-7 3-amino-4-fluorobenzoic acid 
• 67-56-1 methanol 
• 1170669-90-5 4-fluoro-3-iodobenzoyl chloride 
• 403-18-9 3-iodo-4-fluorobenzoic acid 

Downstream Products

• 1170669-84-7 methyl 3-[2-(3,5-bis{2-[4-(2-ethylhexyloxy)phenyl]acetylen-1-yl}phenyl)acetylen-1-yl]-4-fluorobenzoate 

Relevant academic research and scientific papers

Diarylation of N- and O-nucleophiles through a metal-free cascade reaction

The arylation of heteroatom nucleophiles is a central strategy to reach diarylated compounds that are key building blocks in agrochemicals, materials, and pharmaceuticals. Nucleophilic aromatic substitution is a classical tool for such arylations, and recent developments in hypervalent iodine-mediated arylations allow a wider scope of products. Herein, we combine the benefits of these strategies to enable an efficient and transition-metal-free difunctionalization of N- and O-nucleophiles with two structurally different aryl groups and to provide di- and triarylamines and diaryl ethers in one single step (>100 examples). The core of this strategy is the unique reactivity discovered with specifically designed fluorinated diaryliodonium salts, which unveils novel reaction pathways in hypervalent iodine chemistry. The methodology is suitable for diarylation of aliphatic amines, anilines, ammonia, and even water. It tolerates a wide variety of functional and protecting groups, with the retained iodine substituent easily accessible for derivatization of the products.

Development and preliminary evaluation of TFIB, a new bimodal prosthetic group for bioactive molecule labeling

The new readily available prosthetic group, tetrafluorophenyl 4-fluoro-3-iodobenzoate (TFIB), designed for both molecular imaging and targeted radionuclide therapy purposes was radiolabeled either with fluorine or iodine radionuclides with excellent radiochemical yields and purities. These radiolabeled tags were conjugated to N,N-diethylethylenediamine to give melanin-targeting radiotracers [125I]9 and [18F]9, which were successfully evaluated by PET and gamma scintigraphic imaging in B16F0 pigmented melanoma-bearing C57BL/6J mice. Then, radiolabeled [125I]/[18F]TFIB was used to tag tumor-targeting peptides (i.e., PEG3[c(RGDyK)]2 and NDP-MSH targeting αvβ3 integrin and MC1R receptors, respectively) in mild conditions and with good radiochemical yields (47-83% d.c.) and purities (>99%). The resulting radiolabeled peptides were assessed both in vitro and by PET imaging in animal models.

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.

The development of phenylethylene dendrons for blue phosphorescent emitters

New high triplet energy dendrons based on 1,2-diphenylethylene with and without 2-ethylhexyloxy surface groups have been developed for deep blue phosphorescent iridium(III) dendrimers. The fac-tris[1-methyl-5-(4-fluoro) phenyl-3-n-propyl-1H-[1,2,4]triazolyl]iridium(III)-cored dendrimers, bearing first generation 1,2-diphenylethylene dendrons on the ligand triazolyl and phenyl rings, were prepared in excellent yields, employing Sonogashira cross-couplings and palladium catalysed hydrogenation as the key synthetic steps. Both dendrimers showed good thermal stability although the flexible nature of the dendrons led to the materials having low glass transition temperatures. Dendrimer 15 (without the surface groups) emitted good blue phosphorescence with a solution photoluminescence quantum yield (PLQY) of 46%, Commission Internationale de l'Eclairage (CIE) co-ordinates of (0.15, 0.14) and photoluminescence peaks at 441 and 468 nm. The solution PLQY was 50% higher than the parent iridium(III) complex showing that the high triplet energy of the diphenylethylene dendrons does not quench the luminescence of the iridium(III) complex core. Dendrimer 34, which has the surface groups, had a film PLQY of 49% and CIE co-ordinates of (0.16, 0.19) with PL peaks at 441 and 469 nm. The Royal Society of Chemistry 2009.